UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 75

Sortiert nach

GNbAC1, a Humanized Monoclonal Antibody Against the Envelope Protein of Multiple Sclerosis—Associated Endogenous Retrovirus: A First-in-Humans Randomized Clinical Study

Clinical therapeutics, 2012-12, Vol.34 (12), p.2268-2278

2012

Link zum Volltext

Verfügbarkeit prüfen

Preclinical In Vitro and In Vivo Characterization of the Fully Human Monoclonal IgM Antibody KBPA101 Specific for Pseudomonas aeruginosa Serotype IATS-O11

Antimicrobial Agents and Chemotherapy, 2010-06, Vol.54 (6), p.2338-2344

2010

Link zum Volltext

Verfügbarkeit prüfen

MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNbAC1 in multiple sclerosis treatment

Journal of neuroimmunology, 2016-02, Vol.291, p.29-38

2016

Link zum Volltext

Verfügbarkeit prüfen

Pharmacokinetics and Safety Profile of the Human Anti-Pseudomonas aeruginosa Serotype O11 Immunoglobulin M Monoclonal Antibody KBPA-101 in Healthy Volunteers

Antimicrobial Agents and Chemotherapy, 2009-08, Vol.53 (8), p.3442-3446

2009

Link zum Volltext

Verfügbarkeit prüfen

Human Endogenous Retrovirus and Neuroinflammation in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

EBioMedicine, 2016-04, Vol.6, p.190-198

2016

Link zum Volltext

Verfügbarkeit prüfen

Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein

mAbs, 2015-01, Vol.7 (1), p.265-275

2015

Link zum Volltext

Verfügbarkeit prüfen

Human Monoclonal Antibodies as a New Class of Antiinfective Compounds

Clinical & developmental immunology, 2013-01, Vol.2013, p.297120-2

2013

Link zum Volltext

Verfügbarkeit prüfen

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients

Multiple sclerosis, 2015-06, Vol.21 (7), p.885-893

2015

Link zum Volltext

Verfügbarkeit prüfen

Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A Phase 1 study

mAbs, 2016-07, Vol.8 (5), p.854-860

2016

Link zum Volltext

Verfügbarkeit prüfen

B cells alter the phenotype and function of follicular‐homing CXCR5+ T cells

European journal of immunology, 2004-12, Vol.34 (12), p.3562-3571

2004

Link zum Volltext

Verfügbarkeit prüfen

Endogenous retroviral genes, Herpesviruses and gender in Multiple Sclerosis

Journal of the neurological sciences, 2009-11, Vol.286 (1), p.65-72

2009

Link zum Volltext

Verfügbarkeit prüfen

Treatment Against Human Endogenous Retrovirus: A Possible Personalized Medicine Approach for Multiple Sclerosis

Molecular diagnosis & therapy, 2015-10, Vol.19 (5), p.255-265

2015

Link zum Volltext

Verfügbarkeit prüfen

Vaccination of Cystic Fibrosis Patients Against Pseudomonas aeruginosa Reduces the Proportion of Patients Infected and Delays Time to Infection

The Pediatric infectious disease journal, 2004-06, Vol.23 (6), p.504-510

2004

Link zum Volltext

Verfügbarkeit prüfen

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS

Neurology : neuroimmunology & neuroinflammation, 2015-10, Vol.2 (5), p.e144-e144

2015

Link zum Volltext

Verfügbarkeit prüfen

Experience with registered mucosal vaccines

Vaccine, 2003-01, Vol.21 (7), p.678-683

2003

Link zum Volltext

Verfügbarkeit prüfen

Safety and Immunogenicity of Intranasally Administered Inactivated Trivalent Virosome-Formulated Influenza Vaccine Containing Escherichia coli Heat-Labile Toxin as a Mucosal Adjuvant

The Journal of infectious diseases, 2000-03, Vol.181 (3), p.1129-1132

2000

Link zum Volltext

Verfügbarkeit prüfen

Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa

Vaccine, 2006-05, Vol.24 (20), p.4333-4342

2006

Link zum Volltext

Verfügbarkeit prüfen

Prophylaxis and therapy of Pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients

Vaccine, 2004-12, Vol.22, p.S44-S48

2004

Link zum Volltext

Verfügbarkeit prüfen

Mucosal and Systemic Immune Responses in Humans after Primary and Booster Immunizations with Orally Administered Invasive and Noninvasive Live Attenuated Bacteria

Infection and Immunity, 1999-07, Vol.67 (7), p.3680-3685

1999

Link zum Volltext

Verfügbarkeit prüfen

Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis

FEMS immunology and medical microbiology, 2006-07, Vol.47 (2), p.302-308

2006

Link zum Volltext

Verfügbarkeit prüfen

CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function

The Journal of experimental medicine, 2000-12, Vol.192 (11), p.1553-1562

2000

Link zum Volltext

Verfügbarkeit prüfen

Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines

Vaccine, 1998-01, Vol.16 (2), p.298-304

1998

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 75

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(74)
Berichte
(1)

Sprache

Englisch
(75)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(58)
Humans
(56)
Life Sciences & Biomedicine
(56)
Biological And Medical Sciences
(27)
Immunology
(27)
Female
(22)
Adult
(17)
Animals
(17)
Fundamental And Applied Biological Sciences. Psychology
(17)
Male
(17)
Middle Aged
(14)
Mice
(13)
Microbiology
(13)
Pseudomonas Aeruginosa
(13)
Medical Sciences
(11)
Pseudomonas Infections - Prevention & Control
(11)
Antibodies, Monoclonal - Immunology
(10)
Multiple Sclerosis
(10)
Pseudomonas Aeruginosa - Immunology
(10)
Adolescent
(9)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

GNbAC1, a Humanized Monoclonal Antibody Against the Envelope Protein of Multiple Sclerosis—Associated Endogenous Retrovirus: A First-in-Humans Randomized Clinical Study

A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients — A twelve month follow-up

Preclinical In Vitro and In Vivo Characterization of the Fully Human Monoclonal IgM Antibody KBPA101 Specific for Pseudomonas aeruginosa Serotype IATS-O11

MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNbAC1 in multiple sclerosis treatment

Pharmacokinetics and Safety Profile of the Human Anti-Pseudomonas aeruginosa Serotype O11 Immunoglobulin M Monoclonal Antibody KBPA-101 in Healthy Volunteers

Human Endogenous Retrovirus and Neuroinflammation in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein

Human Monoclonal Antibodies as a New Class of Antiinfective Compounds

Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients

Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A Phase 1 study

B cells alter the phenotype and function of follicular‐homing CXCR5+ T cells

Endogenous retroviral genes, Herpesviruses and gender in Multiple Sclerosis

Treatment Against Human Endogenous Retrovirus: A Possible Personalized Medicine Approach for Multiple Sclerosis

Vaccination of Cystic Fibrosis Patients Against Pseudomonas aeruginosa Reduces the Proportion of Patients Infected and Delays Time to Infection

Immunologic monitoring during a phase 2a trial of the GNbAC1 antibody in patients with MS

Experience with registered mucosal vaccines

Re: Errors in the Editorial by Christensen and Giovannoni [HERVs: have we been here before? MSJ 18(12) 1670–1672]

Safety and Immunogenicity of Intranasally Administered Inactivated Trivalent Virosome-Formulated Influenza Vaccine Containing Escherichia coli Heat-Labile Toxin as a Mucosal Adjuvant

Intranasal immunisation with conjugate vaccine protects mice from systemic and respiratory tract infection with Pseudomonas aeruginosa

Prophylaxis and therapy of Pseudomonas aeruginosa infection in cystic fibrosis and immunocompromised patients

Mucosal and Systemic Immune Responses in Humans after Primary and Booster Immunizations with Orally Administered Invasive and Noninvasive Live Attenuated Bacteria

Antibody responses induced by long-term vaccination with an octovalent conjugate Pseudomonas aeruginosa vaccine in children with cystic fibrosis

CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function

Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines

Suchergebnisse filtern